Feasibility Neurocognitive Outcome After Transplant



Status:Recruiting
Conditions:Cancer, Cancer, Blood Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:6 - 21
Updated:1/13/2018
Start Date:December 2014
End Date:December 2018
Contact:Susan Hiniker
Email:shiniker@stanford.edu

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Risk Stratification Model for Neurocognitive Outcome After Transplant and Feasibility of an Early Cognitive Intervention Program

This pilot study will primarily be evaluated by feasibility and adherence to an iPad-based
neurocognitive intervention program. It will secondarily be evaluated by performance on the
neurocognitive testing post-transplant and change in performance in subsequent years.


Inclusion Criteria:

- All patients must have a histologic or cytological diagnosis of ALL treated with stem
cell transplantation. There are no restrictions on prior therapy.

- Patients must be between the ages of 6 years and 21 years of age (inclusive), but
there will be no discrimination based on gender, race, creed, or ethnic background.
The age limits are set at 6 years of age in order to ensure that patients will be able
to participate in these specific cognitive rehabilitation tasks. ECOG/KPS will not be
employed.

- Patient and/or parents/guardians as appropriate must sign an informed consent, be
mentally responsible, able to understand and willing to sign a written informed
consent.

Exclusion Criteria:

- Subjects with significant concurrent medical complications that in the judgment of the
Principal Investigator(s) could affect the patient's ability to complete the planned
trial. There are no therapy restrictions or restrictions regarding the use of other
Investigational Agents.

- Pregnant patients will be excluded.
We found this trial at
1
site
Stanford University School of Medicine
Palo Alto, California 94304
Principal Investigator: Sarah Donaldson
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials